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Abstract
Background: Many patients with schizophrenia and bipolar disorder have impaired insight and low medication
adherence. The aim of this post hoc analysis was to explore the relationship between insight and medication
adherence.
Methods: We included 903 patients with schizophrenia or bipolar disorder who participated in an observational
study conducted in Europe on the outcomes of patients treated with two oral formulations of olanzapine over a
1-year period. Evaluations included Clinical Global Impression (CGI), Global Assessment of Functioning (GAF), insight
(Scale to Assess Unawareness of Mental Disorder, SUMD) medication adherence (Medication Adherence Rating
Scale, MARS), and therapeutic alliance (Working Alliance Inventory, WAI).
Results: Medication adherence was higher in bipolar patients (mean MARS score (SD) 6.5 (2.8) versus 5.8 (2.7) in
schizophrenia; p < 0.001). Patients with schizophrenia had lower insight (i.e., SUMD item 1, unawareness of mental
disorder, mean (SD) of 2.5 (1.3) in schizophrenia versus 1.9 (1.2) in bipolar, p < 0.001). Better insight was associated
with higher adherence (Spearman Correlation Coefficient, SCC, ranging from 0.39 to 0.49 for the three SUMD general
items, p < 0.0001 in all cases). Higher insight was related to a stronger therapeutic alliance (SCC ranging from 0.38 to
0.48, p < 0.0001). A path analysis revealed a positive impact of insight on adherence and alliance and that stronger
alliance was related to lower clinical severity (lower CGI score).
Conclusion: Insight and adherence were found to be closely related. Insight impacts on the therapeutic alliance with
mental health professionals. These factors are associated to treatment outcomes.
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Background
Although a number of psychotropic medications are
available and effective to treat the manifestations of
schizophrenia and bipolar disorder, many patients do
not actually benefit from them due to low adherence
with medication regimens. Rates of low adherence have
been reported to be as high as two-thirds in patients
with schizophrenia [1]. Young et al. also concluded that
40 % of patients treated with conventional antipsychotics
stop taking their medication within one year [2]. Non-
adherence is a particular challenge in schizophrenia due
to the illness association with social isolation, stigma,
and co-morbid substance misuse [3]. Rates of low adher-
ence are also high in patients with bipolar disorder: in a
recent study of 303 patients, 69 % of patients showed
suboptimal adherence [4, 5]. Low adherence rates have
been shown to be one of the main causes of relapse and
hospitalization [6, 7].
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In a recent review in patients with schizophrenia, illness
insight and positive attitude to medication were the only
factors consistently associated with better adherence.
Contradictory results were found for other characteristics
such as socio-demographics, symptom severity and side
effects [8]. Poor insight is a core attribute of schizophre-
nia, occurring in 57–98 % of patients [9, 10] and it is mod-
ulated by positive symptom severity [11]. Lack of insight
has also been reported as one of the most relevant factors
associated with medication adherence in patients with bi-
polar disorder [12].
Insight also impacts on the therapeutic relationship
[7]. In a small sample of inpatients with schizophrenia
or schizoaffective disorder, Misdhahi et al. found that a
weak therapeutic alliance and low insight were associ-
ated with poor adherence in patients with schizophrenia
or schizoaffective disorder [13]. Some studies have actu-
ally studied the relationship between insight, therapeutic
relationship and adherence [14]. However, they were
limited due to small samples of patients or did not in-
clude both in- and outpatients.
Up to now little emphasis has been given to strategies
to increase insight in patients with severe mental disor-
ders. Pijnenbourg et al., in a literature review on treat-
ment for impaired insight in psychosis, confirmed that
insight is a potential therapeutic target and that it is
amenable to improvement. Comprehensive intervention
programmes consisting of multiple components may be
particularly promising [15].
In spite of the increasing research into insight, its causes
and its impact on the course of schizophrenia, many issues
remain unanswered, partly due to the inconsistent defini-
tions of insight but also due to contradictory results about
the impact of insight on patient outcomes [16]. The aim
of this post-hoc analysis was to explore the relationship
between insight, therapeutic relationship and medication
adherence, and their impact on the outcomes of patients
with schizophrenia or bipolar disorder. We hypothesize
that lower insight will result in both a lower medication
adherence and worse therapeutic relationship. Patients
with lower insight will also have worse outcomes, mostly
mediated by the effect of low adherence.
Methods
Study design
Data for this post hoc analysis were obtained from a
prospective, observational (non-interventional), natural-
istic, multicentre, multi-country study designed to com-
pare medication adherence between two oral forms of
olanzapine (either oro-dispersible or standard coated
tablets) in patients with schizophrenia or bipolar dis-
order. Patients were followed for 1 year, with up to five
study visits at approximately 3-month (±1 month) inter-
vals. Data collection occurred when patients attended
for their regular clinic visits. To reduce selection bias,
each participating psychiatrist was asked to enroll con-
secutively, up to eight eligible patients.
Patients
Patients were eligible for enrolment if they met the follow-
ing entry criteria: adult patients diagnosed with schizophre-
nia or any type of bipolar disorder and for whom their
physician decided to begin antipsychotic treatment with
olanzapine (either oro-dispersible or standard coated tab-
let), according to the approved marketing authorization,
within the last 45 days (either as treatment initiation or as
switch from another antipsychotic). A total of 903 patients
with schizophrenia or bipolar disorder from outpatient or
hospital settings were enrolled in this study between April
2007 to April 2008, and the last study visit occurred in May
2009. The protocol did not restrict use to antipsychotic
monotherapy or combination therapy. All treatment
decisions were made at the discretion of the treating
physician and patient, including the choice of olanza-
pine formulation.
All patients provided written, informed consent. The
study was approved by ethical review boards as required by
local law and was conducted in accordance with the ethical
principles that have their origin in the Declaration of
Helsinki. The specific ethics committees that approved the
study are: (1) Comité consultatif sur le traitement de
l'information en matière de recherche dans le domaine
de la santé (France); (2) Landesärztekammer Hessen
Ethik-Kommission (Germany); (3) Papageorgiou Regional
General Hospital of Thessaloniki (Greece). Further details
about the study have been published previously [17].
Clinical assessments
Assessments were conducted by participating psychia-
trists or their designees. All investigators participated in
a start-up meeting in which training in the study proce-
dures and questionnaire administration were provided.
No formal assessment of inter-rater agreement was per-
formed, however the included questionnaires and scales
are commonly used in clinical practice.
Assessments included clinical severity, global functioning,
adherence, insight and the therapeutic alliance. Clinical se-
verity was measured with the Clinical Global Impression
(CGI) scale for Bipolar Disorder (CGI-BP) [18] or Schizo-
phrenia (CGI-SCH) [19]. The Global Assessment of Func-
tioning Scale (GAF) was employed to measure functioning
[20]. Medication adherence was estimated using the
Medication Adherence Rating Scale (MARS), a 10-item
self-reported measure ranging from 0 to 10 with a high
score being associated with better adherence [21].
Insight was measured with the Scale to Assess Unaware-
ness of Mental Disorder (SUMD) [22]. The analyses in-
cluded here report on the first three items of the SUMD
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scale, which rate the unawareness of illness regarding hav-
ing a mental disorder (SUM1), response to medication
(SUM2) and the patient’s perception of the need for medi-
cation (SUM3). The scale is rated from 1 to 5 with higher
ratings indicating higher unawareness/lower insight. Thera-
peutic alliance was assessed with the Working Alliance In-
ventory (WAI) [23]. This is a physician-reported scale that
describes the relationship of the physician with the patient.
The scale results range from 36 (minimum) to 252
(maximum), and higher ratings indicate a better
relationship.
Statistical analysis
Overall baseline patient characteristics by diagnosis were
described and compared using the Chi-square test (for
categorical variables) or Kruskal-Wallis test (for continu-
ous variables). Spearman Correlation Coefficients (SCC)
were employed to assess the associations between vari-
ables at baseline and between the changes from baseline
to endpoint. The variables of the change scores were com-
puted as the difference between baseline and endpoint in
a way that greater difference means more improvement.
Linear regression models were used to assess the effect of
baseline insight components (separately) on outcomes at
endpoint, adjusting for significant covariates. Covariates
for the models were selected based on clinical criteria and
descriptive analyses. Models including and not including
the baseline rating of the outcome measure were fitted. A
path analysis was used to understand the relationship be-
tween insight, adherence, therapeutic alliance and out-
comes. The fit indices that were calculated included the
root mean squared error (RMSEA) (good fit if <0.08),
comparative fit index (CFI) (good fit if >0.95) and
standardized root mean square residual (SRMR) (good
fit if <0.05). The statistical analysis was carried out
using SAS software (SAS Institute, Cary, NC, USA),
version 9.3 and M-Plus 7.2.
Results
Patient demographics and clinical characteristics at
baseline
Out of the 903 enrolled outpatients, 612 (67.8 %) had
been diagnosed with schizophrenia and 291 (32.2 %)
with bipolar disorder. A total of 493 patients (54.6 %) re-
ceived orodispersible olanzapine tablets, whereas 410
(45.4 %) received standard coated olanzapine tablets,
with similar proportions of the different formulations
used in both diagnostic groups. Most patients (n = 735,
81.4 %) were treated in private ambulatory settings,
while the remainder (n = 168, 18.6 %) came from hos-
pital ambulatory settings. Table 1 presents further pa-
tient characteristics. The bipolar patient group were
older and had a higher proportion of women. There
were no differences in the psychiatric care setting
between the two diagnostic groups. Compared with the
schizophrenia patients, bipolar patients appeared to have
significantly better general functioning, as shown by
higher GAF scores. Medication adherence and insight
were also higher in the bipolar patients.
At baseline, patients with higher insight into their
mental disorder were associated with higher medication
adherence scores (SCC between each item of the
SUMD and the MARSS ranged from −0.39 to −0.49, p
< 0.0001 in all cases; Table 2) and a stronger thera-
peutic alliance (SCC between each item of the SUMD
and the WAI score ranged from −0.38 to −0.48, p <
0.0001; Table 2). Higher insight at baseline was also as-
sociated with milder clinical severity (SCC between the
SUMD items and the CGI score ranged from 0.29 to
0.39, p < 0.0001; Table 2) and better global functioning
(SCC between the items of the SUMD and the GAF
score ranged from −0.31 to −0.34, p < 0.0001; Table 2).
A better patient–physician relationship was also associ-
ated with stronger medication adherence, superior glo-
bal functioning, and a milder clinical severity of the
mental illness.
Table 1 Baseline demographics and clinical characteristics of
patients
Characteristics Overall Schizophrenia Bipolar p
(n = 903) (n = 612) (n = 291)
Gender, n (%) females 405 (44.9) 231 (37.7) 174 (59.8) <0.001
Age (years);
mean (SD)
40.9 (13.1) 39.2 (12.7) 44.6 (13.1) <0.001
Insight
SUM1 total score,
mean (SD)
2.3 (1.3) 2.5 (1.3) 1.9 (1.2) <0.001
SUM2 total score,
mean (SD)
2.1 (1.2) 2.3 (1.3) 1.9 (1.1) <0.001
SUM3 total score,
mean (SD)
2.0 (1.0) 2.1 (1.0) 1.8 (1.0) <0.001
Medication adherence
MARS total score,
mean (SD)
6.0 (2.8) 5.8 (2.7) 6.5 (2.8) <0.001
Therapeutic alliance
WAI total score,
mean (SD)
188.5 (27.0) 185.0 (27.4) 195.9 (24.5) <0.001
Clinical severity
CGI total score,
mean (SD)
4.0 (1.2) 4.0 (1.1) 3.9 (1.4) 0.305
Global functioning
GAF total score,
mean (SD)
54.0 (16.0) 51.9 (15.7) 58.4 (15.6) <0.001
CGI clinical global impression, GAF global assessment of functioning, MARS
medication adherence rating scale, SUM1 unawareness of having a mental
disorder, SUM2 unawareness of response to medication, SUM3 unawareness of
the need of medication, WAI working alliance inventory
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Change of patient insight, medication adherence,
therapeutic alliance and clinical outcomes from baseline
to endpoint
After 1 year of follow up, significant direct associations
were found between an improvement in the patient’s
awareness of their mental disorder (i.e., gain of insight)
or an improvement in the patient–physician relationship
and an increase in medication adherence, amelioration
of global functioning and an improvement in the clinical
outcome. Evidence of this was the positive correlation
between the changes of the scores of all SUMD items or
of the WAI scale with those of MARS, GAF, and CGI
scores from baseline to endpoint (Table 3, all p < 0.001).
At the same time, the improvement in patient insight
was accompanied by a strengthening of the patient–
physician relationship.
Linear regression models were used to analyse the
contribution of the different factors on clinical outcomes
at the end of the study, as measured using the CGI and
GAF, adjusting for covariates.
As shown in Table 4, the baseline ratings of the SUMD
items were significantly correlated to the 1-year ratings
of the CGI and GAF scales. MARS and WAI baseline
ratings were also correlated to 1-year GAF ratings. The
linear model which adjusted by baseline covariates and
took into account the correlation among insight, thera-
peutic alliance and adherence (Table 3) showed that the
baseline ratings of the first and second items of the
SUMD scale (SUM1 and SUM2) were associated to the
CGI and GAF at endpoint: worse insight (higher SUM1
and SUM2 scores) was associated to greater overall clin-
ical severity (CGI score) and lower functioning (lower
GAF score). Baseline therapeutic alliance was also asso-
ciated to one year CGI and GAF scores, with better
therapeutic alliance being associated to lower clinical se-
verity and better functioning.
A linear regression model including the baseline score
of the outcome scale was also fitted and provided different
results. In this model the relationship between the baseline
rating of the SUMD items and the CGI and GAF at one
year changed. Thus, SUM1 at baseline was not associated
to CGI or GAF score at one year (regression coefficients
0.01 (95 % CI −0.06; 0.07) and 0.14 (−0.68, 0.97) re-
spectively). SUM2 an SUM3 ratings were associated to
endpoint GAF score (regression coefficients 1.05 (0.11;
1.99) and 2.49 (1.34; 3.64), respectively) but not to end-
point CGI score (regression coefficients −0.02 (−0.09;
0.06) and −0.06 (−0.15; 0.03), respectively). Finally,
MARS and WAI score were both associated to endpoint
CGI (regression coefficients 0.05 (0.02; 0.08) and −0.01
(−0.01; −0.004), respectively) and endpoint GAF scores
(regression coefficients-0.41 (−0.80;-0.01) and (0.10 (0.06;
0.14 respectively) . R2 in all models values ranged from
0.09 to 0.10, which is low given the large number of
factors impacting on the course of schizophrenia. How-
ever, it can be observed that the direction of the rela-
tionship changes when including the baseline rating of
the covariate, which shows the high relationship among
the variables.
Model of interferences between different parameters
Given the intense relationship between insight, thera-
peutic relationship and adherence, a path analysis was
fitted to better understand these associations and how
they influenced outcomes. Figure 1 presents the associ-
ation of baseline ratings of the SUM1 (insight), WAI
(therapeutic relationship) and MARS (adherence with
medication) with GAF (functioning) at 1 year. As GAF
at baseline was also highly correlated with GAF at end-
point, GAF at baseline was also included in the model.
The model showed that, at baseline, lower insight was
associated with lower adherence and a worse therapeutic
relationship. The three variables were also associated
with baseline GAF rating: better insight, better
Table 2 Correlation between insight, medication adherence,
therapeutic working alliance, CGI and GAF at baseline (all
patients)
SUM1 SUM2 SUM3 MARS WAI CGI
SUM1
SUM2 0.72#
SUM3 0.71# 0.78#
MARS −0.39# −0.46# −0.49#
WAI −0.38# −0.42# −0.48# 0.49#
CGI 0.32# 0.39# 0.29# −0.28# −0.16#
GAF −0.31# −0.36# −0.34# 0.26# 0.23# −0.64#
CGI clinical global impression, GAF global assessment of functioning, MARS
medication adherence rating scale, SUM1 unawareness of having a mental
disorder, SUM2 unawareness of response to medication, SUM3 unawareness of
the need of medication, WAI working alliance inventory
Table 3 Correlation amongst change in variables from baseline
to endpoint (all patients)
CGI WAI GAF SUM1 SUM2 SUM3
MARS 0.33# 0.44# 0.41# 0.34# 0.40# 0.44#
CGI 0.29# 0.62# 0.33# 0.35# 0.32#
WAI 0.40# 0.31# 0.35# 0.37#
GAF 0.37# 0.40# 0.40#
SUM1 0.54# 0.53#
SUM2 0.63#
As higher ratings in some scales mean better outcomes and lower ratings in
other scales mean better outcomes, the signs of Pearson correlation
coefficients have been modified so that positive coefficients mean
improvement in one variable is positively correlated with improvement in
the other
CGI clinical global impression, GAF global assessment of functioning, MARS
medication adherence rating scale, SUM1 unawareness of having a mental
disorder, SUM2 unawareness of response to medication, SUM3 unawareness of
the need of medication, WAI working alliance inventory
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therapeutic relationship, and better adherence were all
of them associated with better functioning. Therapeutic
relationship, adherence and baseline GAF were also as-
sociated with 1-year GAF. The stronger relationship
was between baseline and endpoint GAF score. A bet-
ter therapeutic relationship was associated with better
functioning, but greater adherence appeared to be asso-
ciated with slightly poorer functioning. The model was
saturated, and thus no fit indices could be calculated.
We calculated the fit indices for the same model but
not including the relationship between SUM1 and base-
line GAF. In this case the parameters that evaluated
model fit were good for CFI (0.97 which is >0.95) and
SRMR (0.044, which is <0.05) and moderate for
RMSEA (0.115, which is > 0.08). Additional analyses
were conducted stratifying diagnostic group. Very simi-
lar results were found (Fig. 2).
Discussion
Insight, therapeutic alliance with the treating psychiatrist
and medication adherence are highly correlated in pa-
tients with schizophrenia and bipolar disorder. The three
factors co-vary during the course of the disorder and an
improvement in one is accompanied by improvements
in the others. It is worth mentioning that these associa-
tions may be bi-directional: while insight may influence
therapeutic relationship, therapeutic relationship may
also influence insight. These factors are also related to
patient outcomes. However, their independent relation-
ship to patient outcomes is complex as it is difficult to
disentangle the interrelationship between these variables
in a prospective analysis of the course of the disorder.
Our results are consistent with previous studies that
have analysed the relationship between these variables.
For example, a cross-sectional study of patients with
schizophrenia or bipolar disorder admitted due to acute
exacerbation of their condition found that insight was
related to patient attitude towards antipsychotic treat-
ment at hospital discharge [24]. Another cross-sectional
study with 38 inpatients who met ICD-10 criteria for
schizophrenia or schizoaffective disorder showed that
therapeutic alliance was significantly correlated with ad-
herence and that a weak therapeutic alliance and low
insight were associated with poor adherence [13]. Simi-
lar results have been reported for outpatients. A cross-
sectional sample of 150 outpatients with schizophrenia
Table 4 Relationship between baseline insight, adherence and therapeutic relationship and CGI and GAF at endpoint (all patients)
Univariate relationship (correlation coefficient) Regression analysis coefficient (95 % CI)
Baseline value CGI GAF CGI GAF
SUM1 0.12# −0.18# 0.13 (0.06; 0.20)#a −1.76 (−2.69; −0.84)#a
SUM2 0.14# −0.16# 0.14 (0.07; 0.22)#a −1.31 (−2.37; −0.25)*a
SUM3 0.09* −0.13# 0.08 (−0.02; 0.17)a −0.48 (−1.81; 0.84)a
MARS −0.07 0.14# 0.02 (−0.01; 0.05)b −0.02 (−0.47;0.44)b
WAI −0.15+ 0.23# −0.01 (−0.01; −0.004)#b 0.13 (0.08; 0.17)#b
As higher ratings in some scales mean better outcomes and lower ratings in other scales mean better outcomes, the signs of Pearson correlation coefficients have
been modified so that positive coefficients mean improvement in one variable is positively correlated with improvement in the other
CGI clinical global impression, GAF global assessment of functioning, SUM1 unawareness of having a mental disorder, SUM2 unawareness of response to
medication, SUM3 unawareness of the need of medication, MARS medication adherence rating scale, WAI working alliance inventory
#p < 0.001
*p < 0 .05
+p < 0.01
aAdjusted for country, age, sex, MARS and WAI
bAdjusted for country, age, sex, MARS, WAI and SUM1
Fig. 1 Path analyses relating insight, therapeutic working alliance, adherence and global assessment of functioning at endpoint (all patients)
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analysed using a structural equation model, for example,
found evidence for a mediational model in which insight
contributed to medication adherence via patients’ per-
ceived necessity of antipsychotics [14].
Few studies have included follow-up assessment. In a
small study of 112 participants with schizophrenia or
schizoaffective disorder followed for 6 months, Baloush-
Kleinman et al. reported that adherent participants
showed more insight into their illness, awareness of the
need for medication and positive perceptions of trust in
the patient–physician therapeutic alliance. In this study,
structural equation modelling also showed that over
6 months, symptom severity, awareness for the need for
medication and attitudes to medication predicted adher-
ence [25].
Our study expands on previous findings by including a
much larger sample of patients, a longer follow-up, and
analysing the concurrent relationship between these factors.
We have also found consistent results for the overall sam-
ple, and for patients with schizophrenia and bipolar dis-
order, respectively.
This study also raises some questions that deserve further
exploration to fully understand the complex relationship
between insight, therapeutic relationship, adherence and
outcomes. For example, we found that baseline adherence
was directly associated with slightly lower functioning at
1 year. However, baseline adherence was associated with
better functioning at baseline, and baseline functioning was
highly related to better functioning at 1 year. A possible ex-
planation of this counterintuitive finding is that patients
with lower adherence at baseline had a greater capacity for
improvement during the course of the study. Thus patients
with lower adherence at baseline showed greater improve-
ment during the course of the study. In understanding the
predictors and also the effects of good adherence, other fac-
tors, such as the specific anti-psychotic medication and
dose regimen may also be relevant. Treatment dose has
been associated to differences in adherence rates [26] and
also proper antipsychotic dosing may be necessary for the
maximization of treatment outcomes [27].
Several previous studies have also analysed the com-
plex relationship between these variables and their rela-
tionship with other clinical factors. Insight has been
associated with cognitive impairments in schizophrenia
such as social cognition and may also be related to de-
pression [28]. Patients with more metacognitive abilities
may also have a better insight, which seems to be inde-
pendent of neurocognitive deficits [29].
The implications of these findings for patient care are
that interventions to enhance medication adherence are
Patients with schizophrenia (n=603)
Patients with bipolar disorder (n=291)
GAF Baseline
GAF
MARSS
0.25*
0.06
0.14*0.40*
0.10*
0.58*0.02
0.12*0.35*
WAI
SUM D
1
GAF Baseline
GAF
MARSS
0.23*
0.08
0.10
0.40* 0.04
0.58*0.10
0.21*0.36*
WAI
SUM D
1
Fig. 2 Path analyses relating insight, therapeutic working alliance, adherence and global assessment of functioning at endpoint, stratified by
diagnostic group
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particularly appropriate in patients with low illness insight.
Specifically, newly developed treatments that have been
proven efficacious in improving insight in patients with
schizophrenia may lead to better outcomes. For example,
the findings that insight may be related to metacognition
lead to the development of metacognitive intervention of
Lysaker and colleagues [30]. In addition, Van Donkersgoed
and colleagues have developed the MERIT (Metacognitive
Reflection and Insight Therapy) [31]. Given the associ-
ation between insight, the therapeutic alliance and medi-
cation adherence, specific approaches are needed to
improve the therapeutic alliance with the treating team in
patients with low insight, as this alliance impacts directly
on adherence. Brent has developed a mentalization-based
treatment to improve therapeutic relationship [32]. It has
also been suggested that interventions to enhance adher-
ence in schizophrenia may be more effective if they focus
on treatment-related attitudes, particularly the patient’s
perceived necessity for antipsychotic treatment, by explor-
ing and addressing concerns and the patient’s distrust of
pharmacotherapy in a more personalized way [14].
Limitations
A number of limitations should be taken into account
when considering the findings of this analysis. Firstly
the data were drawn from an observational study. Sec-
ondly, assessment of the factors was performed by the
same evaluator, which may have increased the inter-
relationship of the variables. Thirdly the current ana-
lysis included both patients with schizophrenia and
those with bipolar disorder. However, the results are
similar when conducting separate analyses for patients
with schizophrenia and bipolar disorder. Fourth, we
have not included medication in the analyses because
all patients were taking two different formulations of
the same agent and the main report from the original
study found no major differences in outcomes between
the two formulations [17]. Fifth, we have only analyzed
some of the factors that can be related to patient out-
comes (for example, clinical subtypes or family and so-
cial environment were not analyzed). Sixth, the MARS
is a self-reported scale and thus subject to bias. Finally,
this was a post-hoc analysis with only one evaluation at
follow-up; more data points during the course of the
disorder may be necessary to fully understand the rela-
tionship between these variables.
Conclusions
The present study found that insight, therapeutic alli-
ance and adherence are closely related and that all of
these factors impact on clinical and functional status in
patients with schizophrenia or bipolar disorder. These
results highlight the relevance of interventions designed
to improve insight and medication adherence. Improve-
ment in insight is likely to lead to increased adherence
and improvements in the therapeutic alliance.
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